Literature DB >> 1525606

Pharmacokinetics of high dose thiotepa in children undergoing autologous bone marrow transplantation.

M Kletzel1, G L Kearns, T G Wells, H C Thompson.   

Abstract

Pharmacokinetics of high dose thiotepa was studied in 10 children who received this drug as a 2 h infusion at a dose of 300 mg/m2 daily for 3 days. The thiotepa was quantitated using a modification of a previously published gas chromatographic method. Samples were obtained at predetermined times post infusion. The peak plasma concentrations immediately following the infusion ranged from 5.5 to 25.2 (2.0 +/- 6.6) mg/l and the 8 h post infusion ranged from 0.06 to 0.7 (0.32 +/- 0.21) mg/l. The disposition of thiotepa was best described as a simple one compartment open model. The mean (+/- SEM) values for apparent elimination half-life (t1/2 beta), total plasma clearance (CL) and steady volume of distribution (VDss) were 1.3 x h, 11.25 (1.73) l/h/m2 and 19.38 (2.58) l/m2 respectively. In conclusion the pharmacokinetics of high dose thiotepa in children between 2 and 12 years of age do not appear to vary from those reported in children receiving 75 mg/m2 or adults receiving similar doses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525606

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Authors:  A D Huitema; R A Mathôt; M M Tibben; J H Schellens; S Rodenhuis; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

2.  Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

Review 3.  Paediatric labelling requirements. Implications for pharmacokinetic studies.

Authors:  J T Wilson; G L Kearns; D Murphy; S J Yaffe
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

4.  High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group.

Authors:  Perrine Marec-Berard; Céline Segura-Ferlay; Marie-Dominique Tabone; Helene Pacquement; Cyril Lervat; Jean-Claude Gentet; Claudine Schmitt; Nathalie Gaspar; Laurence Brugières
Journal:  Sarcoma       Date:  2014-02-04

5.  In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.

Authors:  Susanna J E Veringa; Dennis Biesmans; Dannis G van Vuurden; Marc H A Jansen; Laurine E Wedekind; Ilona Horsman; Pieter Wesseling; William Peter Vandertop; David P Noske; GertJan J L Kaspers; Esther Hulleman
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.